viral
respiratori
infect
common
diseas
seen
humankind
affect
mostli
children
virus
shown
caus
pneumonia
first
year
life
percentag
decreas
approxim
school
age
respiratori
syncyti
viru
rsv
major
viral
respiratori
pathogen
caus
lower
respiratori
tract
infect
lri
bronchiol
pneumonia
infant
young
children
worldwid
present
larg
burden
healthcar
resourc
parainfluenza
influenza
virus
mani
type
adenoviru
rhinoviru
enteroviru
also
coronaviru
herp
simplex
type
virus
also
detect
children
suffer
respiratori
infect
ri
highrisk
group
sever
diseas
especi
rsv
includ
age
less
month
preterm
infant
infant
underli
cardiopulmonari
diseas
andor
immunodefici
antivir
prophylaxi
ri
need
extrem
safe
inexpens
wide
avail
longterm
use
children
far
criteria
success
fulfil
prevent
influenza
infect
influenza
virus
import
caus
acut
ill
consid
age
group
recent
summari
diseas
burden
rank
acut
lri
import
caus
disabilityadjust
life
year
lost
world
popul
impact
lri
greatest
children
younger
year
age
diseas
burden
impos
influenza
justifi
indic
prophylaxi
children
prevent
influenza
children
could
yield
anoth
import
benefit
tel
fax
email
kafetzi
athforthnetgr
import
spreader
influenza
commun
frequent
introduc
household
import
schoolag
children
dissemin
influenza
conclus
demonstr
japanes
program
influenza
immunis
period
influenza
vaccin
coverag
schoolchildren
reach
approxim
estim
death
among
elderli
prevent
annual
main
disadvantag
influenza
vaccin
howev
necess
deliv
vaccin
year
short
interv
time
vaccin
produc
distribut
time
influenza
viru
activ
begin
result
studi
new
intranas
influenza
vaccin
children
pend
howev
avail
influenza
vaccin
recommend
children
older
six
month
chronic
underli
diseas
pulmonari
cardiovascular
renal
metabol
also
immunosuppress
hemoglobinopathi
children
long
term
aspirin
therapi
vaccin
efficaci
prevent
transmiss
usual
elderli
protect
rate
lower
efficaci
prevent
mortal
usual
prophylaxi
andor
treatment
use
amantadin
rimantadin
avail
patient
infect
influenza
viru
howev
vitro
resist
amantadin
rimantadin
document
use
associ
intrafamili
transmiss
resist
influenza
strain
neuraminidas
inhibitor
gain
interest
prevent
treat
influenza
activ
influenza
b
also
emerg
resist
uncommon
agent
becam
avail
influenza
season
clinic
benefit
document
da
kafetzi
administ
within
hour
onset
symptom
treatment
agent
recommend
healthi
adult
patient
asthma
copd
healthi
children
children
asthma
prevent
recommend
within
famili
commun
set
nurs
home
outbreak
adjunct
late
vaccin
best
approach
control
rsv
prevent
spread
rsv
transmit
via
larg
droplet
aerosol
close
contact
within
three
feet
distanc
contamin
fomit
rsv
surviv
minut
cloth
six
hour
hard
surfac
toy
tabletop
stethescop
previous
healthi
children
develop
rsv
infect
may
shed
viru
seven
ten
day
immunocompromis
patient
shed
viru
week
famili
atrisk
infant
children
taught
import
repeat
hand
wash
warn
expos
infant
passiv
smoke
crowd
larg
daycar
centr
rsv
season
limit
contact
individu
obviou
sign
upper
respiratori
tract
infect
effect
rsv
prophylaxi
either
activ
vaccin
passiv
immun
globulin
monoclon
antibodi
form
evalu
past
four
decad
safe
effect
rsv
vaccin
thu
far
develop
vaccin
trial
conduct
healthi
infant
receiv
formalininactivact
vaccin
develop
enhanc
respiratori
diseas
fifteenfold
increas
rsv
lri
hospitalis
rate
includ
sever
fatal
outcom
becam
natur
infect
rsv
follow
respiratori
season
tragic
experi
delay
develop
rsv
vaccin
use
highrisk
preterm
infant
young
children
anticip
vaccin
avail
mani
year
absenc
safe
effect
rsv
vaccin
passiv
immun
prophylaxi
use
humanis
monoclon
rsv
antibodi
develop
palivizumab
synagi
rsv
fproteinspecif
humanis
monoclon
igg
antibodi
neutralis
activ
prevent
viru
fuse
enter
respiratori
epitheli
cell
compound
high
specif
activ
rsv
vitro
formul
high
concentr
permit
administr
small
volum
intramuscular
inject
sinc
deriv
human
plasma
prophylaxi
palivizumab
remov
small
potenti
risk
transmiss
bloodborn
pathogen
winter
impactrsv
trial
multicentr
multicountri
randomis
doubleblind
placebocontrol
trial
palivizumab
conduct
facilit
licensur
synagi
usa
europ
occur
respect
studi
subject
includ
children
younger
two
year
bronchopulmonari
diseas
bpd
chronic
lung
diseas
cld
requir
therapi
bpdcld
within
six
month
studi
entri
children
prematur
gestat
week
gestat
without
cld
month
age
studi
entri
subject
receiv
five
monthli
im
inject
palivizumab
dose
mgkg
placebo
rsvrelat
hospitalis
reduc
clinic
statist
signific
p
signific
reduct
also
observ
favour
palivizumab
recipi
total
rsvrelat
hospit
day
per
children
p
total
rsvrelat
hospit
day
requir
increas
supplement
oxygen
p
total
rsvrelat
hospit
day
lri
score
p
incid
intens
care
unit
admiss
p
addit
studi
perform
result
acquisit
addit
safeti
efficaci
data
paediatr
patient
trial
palivizumab
safeti
reaffirm
new
unanticip
advers
event
occur
placebo
group
use
studi
excel
data
larg
spanish
epidemiolog
studi
iri
demonstr
mean
hospitalis
rate
preterm
infant
week
gestat
age
treat
palivizumab
contrast
outcom
studi
show
mean
hospitalis
rate
around
patient
receiv
palivizumab
prophylaxi
sever
rsv
lri
also
common
preterm
infant
without
cld
infant
underdevelop
lung
receiv
sub
optim
amount
igg
transplacent
mother
spanish
epidemiolog
studi
iri
demonstr
hospitalis
rate
rsv
lri
group
infant
rsv
progress
sever
lower
respiratori
tract
diseas
apnoea
particularli
prematur
young
term
infant
pulmonari
failur
sometim
death
key
element
support
home
hospit
mainten
good
hydrat
aspir
occur
ill
infant
care
feed
essenti
decis
hospitalis
infant
depend
factor
parent
adequaci
care
sick
infant
young
age
month
histori
prematur
presenc
chronic
cardiac
andor
pulmonari
diseas
inabl
take
adequ
fluid
mouth
extrem
lethargi
irrit
toxic
appear
high
respiratori
rate
breathsminut
oxygen
satur
increas
carbon
dioxid
level
use
laboratori
adjunct
decid
whether
hospitalis
infant
assess
risk
pulmonari
failur
tabl
list
gener
class
treatment
use
studi
infant
rsv
lri
hospit
emerg
set
except
use
oxygen
hydrat
none
therapi
proven
consist
use
treat
rsv
lri
bronchodil
may
tri
casebycas
basi
discontinu
child
respond
treatment
use
steroid
current
recommend
cromolyn
proven
use
treatment
acut
bronchiol
ribavirin
licens
antivir
treatment
rsv
usa
europ
reserv
sickest
patient
efficaci
safeti
remain
controversi
occurr
bacteri
infect
except
otiti
media
low
therefor
children
rsv
care
assess
antibiot
use
prescrib
tabl
list
specif
indic
antibiot
parainfluenza
virus
mani
type
adenoviru
rhinoviru
enteroviru
coronaviru
virus
also
affect
children
could
respons
lri
highrisk
group
sever
diseas
includ
young
infant
less
month
age
preterm
infant
infant
underli
cardiopulmonari
diseas
andor
immunodefici
human
parainfluenza
viru
hpiv
group
subgroup
occur
sever
time
year
instanc
occur
biennial
epidem
fall
report
occur
biennial
altern
year
recent
yearli
outbreak
croup
frequent
lri
caus
group
respiratori
syndrom
describ
uniqu
propens
infect
young
infant
isol
small
number
mainli
children
also
adult
adenovir
infect
seem
much
season
variat
howev
less
often
outbreak
may
occur
fall
major
lri
pneumonia
caus
viru
occur
preschoolag
children
rhinovirus
recov
year
round
recov
often
spring
summer
fall
anecdot
use
immunoglobulin
igiv
treat
adenoviru
diseas
immunocompromis
children
report
posit
neg
result
also
igiv
coupl
ribavirin
anecdot
treatment
rsv
hpiv
influenza
b
pneumonia
immunocompromis
patient
ganciclovir
found
inhibitori
effect
adenoviru
vitro
vivo
studi
systemat
controversi
continu
use
vitamin
c
prophylaxi
uri
howev
trial
suggest
vitamin
c
may
protect
lri
pneumonia
children
also
recent
evid
exist
support
role
vitamin
reduc
morbid
mortal
acut
measl
infect
includ
pneumonia
croup
conclus
effect
antivir
prophylaxi
either
activ
vaccin
passiv
monoclon
antibodi
form
virus
avail
palivizumab
synagi
approv
agent
use
prophylaxi
rsv
infect
posit
treatment
approach
good
hydrat
oxygen
supplement
best
approach
prevent
viral
spread
subsequ
ill
educ
famili
hospit
staff
import
infect
control
hand
wash
avoid
passiv
smoke
crowd
hospit
cohort
infant
suffer
lri
respiratori
infect
control
measur
